ResearcherSeoul National UniversityNo recent work listed
Yong‐Tae Kim
Matched on ORCID iD 0000-0002-7843-9705; OpenAlex author ID A5049487679. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper
Papers 3
- Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
- Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. Last author DOI 10.5009/gnl16307↗
- Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182156d5a↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sang Hyub Lee · 3 shared papers, 2011–2021 · strength 0.21
- Paper Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens:… DOI 10.5009/gnl20070↗
- Paper Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of Firs… DOI 10.5009/gnl16307↗
- Paper Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property … DOI 10.1097/mpa.0b013e3182156d5a↗
- Ji Kon Ryu · 3 shared papers, 2011–2021 · strength 0.21
- Paper Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens:… DOI 10.5009/gnl20070↗
- Paper Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of Firs… DOI 10.5009/gnl16307↗
- Paper Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property … DOI 10.1097/mpa.0b013e3182156d5a↗
- Jae Seung Kang · 1 shared paper, 2021 · strength 0.11
- Woo Hyun Paik · 1 shared paper, 2021 · strength 0.11
- Yoo Jin Choi · 1 shared paper, 2021 · strength 0.11
- Hongbeom Kim · 1 shared paper, 2021 · strength 0.11
- Haeryoung Kim · 1 shared paper, 2021 · strength 0.11
- Yoonhyeong Byun · 1 shared paper, 2021 · strength 0.11
- Do‐Youn Oh · 1 shared paper, 2021 · strength 0.11
- Eui Kyu Chie · 1 shared paper, 2021 · strength 0.11
- Hyeong Seok Kim · 1 shared paper, 2021 · strength 0.11
- Jin‐Young Jang · 1 shared paper, 2021 · strength 0.11
- Wooil Kwon · 1 shared paper, 2021 · strength 0.11
- Jae Woo Lee · 1 shared paper, 2017 · strength 0.08
- Dong Kee Jang · 1 shared paper, 2017 · strength 0.08
- Kwang Hyun Chung · 1 shared paper, 2017 · strength 0.08
- Jun Kyu Lee · 1 shared paper, 2011 · strength 0.03
- Won Jae Yoon · 1 shared paper, 2011 · strength 0.03
- Joo Kyung Park · 1 shared paper, 2011 · strength 0.03
- Yong Bum Yoon · 1 shared paper, 2011 · strength 0.03
- Sang Myung Woo · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.